Non-Alcoholic Fatty Liver Disease (NAFLD)

Non-alcoholic fatty liver disease (NAFLD) is a widespread and often silent condition, affecting around 25% of the global population. It involves the buildup of fat in the liver unrelated to alcohol use and includes a spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), which can lead to inflammation, scarring, and advanced liver diseases like cirrhosis and cancer.

Closely linked to obesity, type 2 diabetes, and metabolic syndrome, NAFLD reflects the global rise in these conditions. It can even occur in individuals with normal body weight, a phenomenon called "lean NAFLD," driven by genetic or metabolic factors. Many people are unaware they have NAFLD as it often develops without symptoms. Common signs include elevated liver enzymes or subtle fatigue, with imaging studies such as ultrasound or MRI aiding diagnosis. In advanced cases, tests like FibroScan or liver biopsy may be necessary.

NAFLD’s impact extends beyond the liver. Cardiovascular disease is the leading cause of death among those affected, and it also increases risks of type 2 diabetes, kidney disease, and certain cancers. Early detection is vital for preventing these complications. Treatment centers on lifestyle changes, especially weight loss through a Mediterranean diet and regular exercise. Even modest weight loss of 7–10% can significantly improve liver health and potentially reverse early-stage fibrosis.

Medical advancements are introducing promising therapies, including GLP-1 receptor agonists, such as weekly semaglutide, and other agents targeting liver inflammation and fibrosis. Other medications, including pioglitazone, liraglutide, and vitamin E, have shown promise in clinical trials. However, no medications are yet FDA-approved for NAFLD, making prevention and lifestyle management the primary strategies for addressing the condition.

Unchecked, NAFLD can progress to serious complications like cirrhosis or liver cancer. NASH, the more aggressive form of the disease, poses a particularly high risk for advanced fibrosis and systemic issues, including heart disease and strokes. Preventing NAFLD starts with maintaining metabolic health through diet, exercise, and regular check-ups, particularly for those at higher risk.

At Chia Endocrinology & Wellness, Dr. Farhad Hasan offers expert care for patients with NAFLD. He combines advanced diagnostic testing with evidence-based treatments, helping individuals reverse fatty liver disease and improve their overall health. His personalized approach empowers patients to take control of their well-being through sustainable lifestyle changes and tailored therapies. If you’re concerned about high ALT levels, metabolic syndrome, or your liver health, Dr. Hasan is here to help.

At Chia Endocrinology & Wellness, Dr. Farhad Hasan serves patients across Western Pennsylvania, including the city of Pittsburgh and surrounding areas in Allegheny County such as Ross Township, McCandless, Pine, Marshall, Mars, Richland, Gibsonia, Wexford, Sewickley, Franklin Park, Hampton, Shaler, Findlay, Upper St. Clair, Robinson, North Fayette, Monroeville, and Moon Township. We also serve Butler County, covering Cranberry Township, Seven Fields, Zelienople, Butler, Harmony, and Evans city, as well as patients in nearby Washington County and Beaver County.